Abstract
Cytostatic therapy of patients with lung cancer is attended with decrease in the relative number of T-lymphocytes and their theophylline-resistant population. Patients who were given SB showed a tendency towards increase of these parameters during antitumor chemotherapy. The immunoregulation index (IRI) in this case was approximately twice the background values during the whole period of investigation. The inclusion of SB in the therapeutic complex promotes increase in the number of immunoglobulins A at a stable level of immunoglobulins G.
Publication types
-
Clinical Trial
-
English Abstract
MeSH terms
-
Adjuvants, Immunologic / therapeutic use*
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
B-Lymphocytes / drug effects
-
B-Lymphocytes / immunology
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Endotoxins
-
Humans
-
Immunoglobulin A / blood
-
Immunoglobulin G / blood
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / immunology
-
Lung Neoplasms / pathology
-
Male
-
Methotrexate / administration & dosage
-
Methotrexate / adverse effects
-
Middle Aged
-
Neoplasm Staging
-
Plants, Medicinal*
-
T-Lymphocytes / drug effects
-
T-Lymphocytes / immunology
Substances
-
Adjuvants, Immunologic
-
Endotoxins
-
Immunoglobulin A
-
Immunoglobulin G
-
Doxorubicin
-
Cyclophosphamide
-
Methotrexate